^
    16h
    Dose Individualization of Pemetrexed - IMPROVE-I (clinicaltrials.gov)
    P4, N=6, Completed, Radboud University Medical Center | Phase classification: P2 --> P4
    Phase classification
    |
    pemetrexed • leucovorin calcium
    16h
    Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report. (PubMed, Cancer Chemother Pharmacol)
    The case provides additional support that IT pemetrexed can offer symptomatic relief and may be considered as a treatment option in advanced LM. Furthermore, the case illustrates that an increased dose of lorlatinib may efficiently control LM in patients with ALK-rearranged NSCLC, following progression on standard lorlatinib dosage.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK rearrangement
    |
    Lorbrena (lorlatinib) • pemetrexed
    2d
    Association of PTOV1 and Cyfra21-1 with neoadjuvant chemosensitivity in patients with lung adenocarcinoma. (PubMed, Am J Transl Res)
    PTOV1 and Cyfra21-1 are upregulated in LUAC patients who are resistant to neoadjuvant chemotherapy. Both markers not only have predictive value for chemosensitivity in these patients, but are also independent factors affecting neoadjuvant chemosensitivity.
    Journal
    |
    KRT19 (Keratin 19)
    |
    cisplatin • pemetrexed
    3d
    Tiragolumab and Atezolizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases (clinicaltrials.gov)
    P2, N=3, Active, not recruiting, Liza Villaruz, MD | Recruiting --> Active, not recruiting | N=35 --> 3 | Trial completion date: Apr 2029 --> Aug 2026 | Trial primary completion date: Sep 2027 --> Aug 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058)
    5d
    A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLS) (MK-3475-01G/KEYMAKER U01) (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • patritumab deruxtecan (U3-1402)
    6d
    A Trial of GFH018 and Toripalimab in Combination with Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC (clinicaltrials.gov)
    P2, N=65, Active, not recruiting, Genfleet Therapeutics (Shanghai) Inc. | Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Oct 2024 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    cisplatin • carboplatin • paclitaxel • Loqtorzi (toripalimab-tpzi) • pemetrexed • GFH018
    6d
    An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) (clinicaltrials.gov)
    P3, N=49, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | N=100 --> 49
    Enrollment closed • Enrollment change
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel • Xtandi (enzalutamide) • pemetrexed
    7d
    Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas (clinicaltrials.gov)
    P1, N=321, Recruiting, Inhibrx Biosciences, Inc | N=240 --> 321 | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    cisplatin • carboplatin • 5-fluorouracil • temozolomide • pemetrexed • irinotecan • ozekibart (INBRX-109)
    7d
    A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (clinicaltrials.gov)
    P1, N=230, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Feb 2025 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • MK-0482
    7d
    Pembrolizumab with Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients with Asymptomatic Brain Metastases (clinicaltrials.gov)
    P2, N=13, Completed, Samsung Medical Center | Recruiting --> Completed | N=50 --> 13 | Trial completion date: Feb 2026 --> Dec 2024 | Trial primary completion date: Sep 2025 --> Jun 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed
    8d
    SKYSCRAPER-06: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=542, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: May 2027 --> Dec 2025
    Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058)
    8d
    Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (clinicaltrials.gov)
    P2, N=401, Active, not recruiting, AstraZeneca | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK fusion
    |
    Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed
    9d
    KEYNOTE-483: Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P2/3, N=520, Completed, Canadian Cancer Trials Group | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Apr 2023 --> Oct 2024
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • pemetrexed
    9d
    Study of Eftilagimod Alfa (Efti) in Combination with Pembrolizumab and Chemotherapy Versus Placebo in Combination with Pembrolizumab and Chemotherapy in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) (clinicaltrials.gov)
    P3, N=756, Not yet recruiting, Immutep S.A.S.
    New P3 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • pemetrexed • ImmuFact (eftilagimod alpha)
    9d
    APPEAL: APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC (clinicaltrials.gov)
    P2, N=0, Withdrawn, Sun Yat-sen University | N=128 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement
    |
    carboplatin • AiTan (rivoceranib) • pemetrexed
    10d
    ARC-4: A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (clinicaltrials.gov)
    P1, N=77, Completed, Arcus Biosciences, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)
    12d
    AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (clinicaltrials.gov)
    P1, N=500, Recruiting, Amgen | Trial completion date: Jun 2032 --> Oct 2031 | Trial primary completion date: Jun 2029 --> Oct 2028
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • Lumakras (sotorasib) • pemetrexed • AMG 193
    13d
    NASCR: Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. (clinicaltrials.gov)
    P2, N=0, Withdrawn, Sun Yat-sen University | N=80 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal • Combination therapy
    |
    carboplatin • Loqtorzi (toripalimab-tpzi) • pemetrexed
    13d
    GO30103: Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors (clinicaltrials.gov)
    P1, N=518, Completed, Genentech, Inc. | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • paclitaxel • capecitabine • pemetrexed • etoposide IV • tiragolumab (RG6058)
    15d
    Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. (PubMed, JTO Clin Res Rep)
    Furthermore, patients who received 1L platinum/pemetrexed chemotherapy are often considered for second or further-line (2L+) ipi-nivo on the basis of MAPS2 results. The highest-grade TRAE was 1 to 2 in 58% of these patients and 3 or higher in 42% Treatment discontinuation due to a TRAE occurred in 22% of patients. In this real-world cohort of patients with MPM treated with ipi-nivo survival outcomes were inferior to those reported in the CheckMate-743 and MAPS2 trials, whereas safety outcomes were similar.
    Journal • Real-world evidence • PD(L)-1 Biomarker • Real-world
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • pemetrexed
    16d
    Plasma-Adapted First-Line Pembro in NSCLC (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Julia K. Rotow, MD | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed
    16d
    HORIZON 2: A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=150, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • Alecensa (alectinib) • pemetrexed
    16d
    Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, West China Hospital
    New P2 trial • Metastases
    |
    cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • 5-fluorouracil • doxorubicin hydrochloride • cyclophosphamide • pemetrexed • vindesine
    17d
    A Study of SKB264 in Combination with Pembrolizumab Versus Chemotherapy in Combination with Pembrolizumab As First-Line Treatment for PD-L1 Negative Patients with Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=432, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
    New P3 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • sacituzumab tirumotecan (MK-2870)
    17d
    Safety, Effectiveness, and Pharmacokinetics (the Movement of Drug Into, Through and Out of the Body) of BNT327 (an Investigational Therapy) in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (clinicaltrials.gov)
    P2/3, N=982, Not yet recruiting, BioNTech SE
    New P2/3 trial • Combination therapy
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • BNT327
    17d
    Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors (clinicaltrials.gov)
    P2, N=64, Recruiting, Northwestern University | Not yet recruiting --> Recruiting | Initiation date: May 2025 --> Nov 2024
    Enrollment open • Trial initiation date • Metastases
    |
    pemetrexed
    17d
    AVANZAR: Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=1350, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial completion date: Feb 2027 --> Nov 2027 | Trial primary completion date: Feb 2027 --> Nov 2027
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    EGFR mutation • ALK rearrangement • ROS1 rearrangement • TROP2 positive
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • datopotamab deruxtecan (DS-1062a)
    17d
    The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations. (PubMed, Lung Cancer)
    For patients with EGFR mutant NSCLC who progress on osimertinib, there is a significant PFS, but not OS, benefit to continuing osimertinib with next line platinum pemetrexed chemotherapy. The continuation of osimertinib with next line platinum pemetrexed chemotherapy appears to reduce the risk of CNS progression.
    Journal • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • pemetrexed
    19d
    Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study. (PubMed, J Immunother Cancer)
    Camrelizumab plus carboplatin and pemetrexed as first-line therapy continued to demonstrate long-term OS benefit over carboplatin and pemetrexed, with manageable toxicity. Patients who completed 2 years of camrelizumab had enduring response and impressive OS. Current 5-year updated analysis further supports camrelizumab plus carboplatin and pemetrexed as a standard-of-care for previously untreated advanced non-squamous NSCLC without EGFR/ALK alterations.
    Clinical • P3 data • Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    carboplatin • AiRuiKa (camrelizumab) • pemetrexed
    20d
    EXCLAIM-2: TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations (clinicaltrials.gov)
    P3, N=354, Active, not recruiting, Takeda | Trial completion date: Dec 2024 --> Jul 2025
    Trial completion date • EGFR exon 20
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    cisplatin • carboplatin • pemetrexed • Exkivity (mobocertinib)
    20d
    Tiragolumab and Atezolizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases (clinicaltrials.gov)
    P2, N=35, Recruiting, Liza Villaruz, MD | Trial completion date: Apr 2027 --> Apr 2029 | Trial primary completion date: Sep 2025 --> Sep 2027
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058)
    20d
    Synergistic effects of MK-1775 and gemcitabine on cytotoxicity in non-small cell lung cancer. (PubMed, Heliyon)
    MK-1775 enhances the cytotoxic effects of gemcitabine and pemetrexed in NSCLC cell lines and effectively inhibits tumor growth in vivo. These findings suggest that Wee1 inhibition by MK-1775, combined with chemotherapy, represents a promising therapeutic strategy for NSCLC treatment.
    Journal • PARP Biomarker
    |
    TP53 (Tumor protein P53) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CDK1 (Cyclin-dependent kinase 1)
    |
    TP53 mutation
    |
    gemcitabine • pemetrexed • adavosertib (AZD1775)
    22d
    COMPEL: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=98, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date • Metastases
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed
    22d
    Development of Potent and Selective Inhibitors of Methylenetetrahydrofolate Dehydrogenase 2 for Targeting Acute Myeloid Leukemia: SAR, Structural Insights, and Biological Characterization. (PubMed, J Med Chem)
    Furthermore, synergistic effects were observed when combining potential compounds with Alimta. Compound 16e emerged as a leading candidate, demonstrating superior inhibition and selectivity for MTHFD2, favorable pharmacokinetics, and potent antitumor efficacy in MOLM-14 xenograft models.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • MTHFD2 (Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2)
    |
    FLT3-ITD mutation
    |
    pemetrexed
    23d
    A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma (clinicaltrials.gov)
    P2, N=660, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial primary completion date
    |
    cisplatin • gemcitabine • cyclophosphamide • pemetrexed • vincristine • Erivedge (vismodegib)
    23d
    A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene (clinicaltrials.gov)
    P1, N=190, Not yet recruiting, Pfizer
    New P1 trial • Combination therapy • IO biomarker • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • sasanlimab (PF-06801591) • PF-07284892
    23d
    Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=430, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P3 trial • Metastases
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed
    23d
    Biological and clinical characteristics of non-small cell lung cancer non-specific subtype. (PubMed, Heliyon)
    Among 69 patients with complete treatment information, 58 received platinum-based chemotherapy, with paclitaxel being the most commonly used combination chemotherapy drug (n = 25), followed by pemetrexed (n = 21). Paclitaxel with immunotherapy may have better benefits as a first-line treatment. Anatomic location and immunotherapy use are prognostic factors.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
    |
    KRAS mutation • EGFR mutation
    |
    paclitaxel • pemetrexed
    24d
    COPERNICUS: A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=365, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • amivantamab SC (Ami-LC)
    27d
    A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=101, Active, not recruiting, Bristol-Myers Squibb | N=402 --> 101 | Trial primary completion date: Oct 2025 --> Aug 2024
    Enrollment change • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • paclitaxel • pemetrexed • BMS-986408
    27d
    Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors (clinicaltrials.gov)
    P2, N=64, Not yet recruiting, Northwestern University | Trial completion date: May 2031 --> May 2030 | Trial primary completion date: May 2030 --> May 2029
    Trial completion date • Trial primary completion date • Metastases
    |
    pemetrexed
    29d
    A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Mar 2028 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)